Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q2 FY2026 Earnings Presentation
20 slides from Piramal Pharma's earnings presentation, November 2025
Slide 1: Q2FY26 Results
Q2FY26 Results November 2025
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner,
Slide 3: Diversified Global Pharma and Wellness Company
Diversified Global Pharma and Wellness Company Built a Company with Portfolio of Differentiated Products and Services, and Commercial Presence in 100+ Countries CDMO Business Complex Hospital Generics Business Consumer Healthcare Business Integrated CDMO Company A Critical Care Company Consumer Heal
Slide 4: Key Financial Highlights – Q2/H1 FY2026
Key Financial Highlights – Q2/H1 FY2026 Revenue from Operations EBITDA & EBITDA Margin Historically, H2 has Outperformed H1 (In ₹ Crore) (EBITDA: In ₹ Crore) EBITDA Margin % of Full Year Revenue H1 H2 (5)% 15% 10% 55 55 54 4,193 3,977 627 389 45 45 46 H1FY25 H1FY26 H1FY25 H1FY26 FY23 FY24 FY25 % of
Slide 5: Business Wise Performance
Business Wise Performance
Slide 6: CDMO Business
CDMO Business Performance Highlights Revenue Growth (In ₹ Crore) ❖ YoY performance during Q2 and H1 FY26 impacted by: (14)% (21)% • Inventory destocking in one large on-patent commercial product by the customer. • Slower early-stage discovery and development order inflows in H1FY26 due to inconsiste
Slide 7: Strong Customer Interest for our US Sites
Strong Customer Interest for our US Sites Steadily Increasing our Footprint in the US Initiated US$ 90 Mn investment to expand Lexington and Riverview Our Presence in the US facilities, part of our ADCelerate programme :- 3 Manufacturing and • Lexington:- Adding commercial-scale sterile injectables
Slide 8: Dedicated Suite to Enhance OSD Production at Sellersville, USA
Dedicated Suite to Enhance OSD Production at Sellersville, USA PPDS, India The multi-million-dollar joint investment with Played crucial role in product development NewAmsterdam Pharma will provide commercial capacity for fixed dose combination of Obicetrapib and Ezetimibe to meet commercial demand.
Slide 9: Complex Hospital Generics Business
Complex Hospital Generics Business Performance Highlights Revenue Growth (In ₹ Crore) ❖ Inhalation Anesthesia 1% 0% • Continue to consolidate our #1 position in the mature US Sevoflurane market, with value share of 45% in Mar’25 - up from 44% in MAT Mar’24. (Source:- IQVIA) 1,274 1,281 • To drive gr
Slide 10: Piramal Consumer Healthcare Business
Piramal Consumer Healthcare Business Performance Highlights Revenue Growth (In ₹ Crore) ❖ 15% Revenue growth in Q2 and H1 FY26 – faster than market growth. 15% 15% ❖ Power Brands grew 20% YoY during Q2FY26, contributing 51% to total PCH sales. • Growth was driven by Little’s, Lacto Calamine, CIR, an
Slide 11: Focus on Power Brands with Brand Promotion and Marketing
Focus on Power Brands with Brand Promotion and Marketing (In ₹ Cr) Investments in Brand Promotion and Marketing % of PCH 15% 13% 11% 12% 12% sales 131 131 125 66 73 FY23 FY24 FY25 H1FY25 H1FY26 (In ₹ Cr) Strong Growth in our Power Brands 21% CAGR 19% 538 310 370 448 260 FY23 FY24 FY25 H1FY25 H1FY26
Slide 12: Joint Venture with AbbVie
Joint Venture with AbbVie AbbVie Therapeutics India Private Limited, a joint venture between AbbVie and PPL, is one of the market leaders in the ophthalmology therapy area in the Indian pharma market Ownership Ownership 49% 51% In FY2025, the JV reported revenue of ₹494 Cr. with PAT margin of 28% Br
Slide 13: Financials
Financials
Slide 14: Consolidated Financials Highlights
Consolidated Financials Highlights (in ₹ Cr. or as stated) Particulars Q2FY26 Q2FY25 YoY Change Q1FY26 QoQ Change H1FY26 H1FY25 YoY Change Revenue from Operations1 2,044 2,242 (9)% 1,934 6% 3,977 4,193 (5)% CDMO 1,044 1,324 (21)% 997 5% 2,041 2,381 (14)% CHG 644 643 0% 637 1% 1,281 1,274 1% ICH 319
Slide 15: Consolidated Financials Highlights
Consolidated Financials Highlights (in ₹ Cr. or as stated) Key Balance Sheet Items As on 30-Sep-25 As on 31-Mar-25 Total Equity 8,073 8,125 Net Debt 3,971 4,199 Total 12,045 12,324 Net Fixed Assets 9,394 9,110 Tangible Assets 4,655 4,534 Intangible Assets including goodwill 3,651 3,599 CWIP (includi
Slide 16: Sustainability
Sustainability
Slide 17: Innovating Responsibly. Growing Sustainably.
Innovating Responsibly. Growing Sustainably. Access the full report Sustainability Purpose Piramal Pharma Sustainability Operating Responsibly. Report FY 2025 Growing Sustainably. Scan Me to view report Sustainability Vision To become a globally leading integrated pharmaceutical company, operating o
Slide 18: Embedding Sustainability in Every Step of Our Growth
Embedding Sustainability in Every Step of Our Growth Responsible Operations Zero 2.10 Lakh 10.5% 14.08% Hazardous Waste to Landfill Kiloliters of Freshwater Reduction in Scope 1 & 2 Total Energy Sourced from Bio- Saved Emissions Over Base Year Briquettes/Biomass (FY22) Business Resilience 50% 100% 2
Slide 19: Dial-in Details for Q2 and H1 FY26 Earnings Conference Call
Dial-in Details for Q2 and H1 FY26 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 09:30 AM IST 1 800 120 1221 (Toll free number) USA – 11:00 PM Toll free number Conference call (Eastern Time – New York) 18667462133 th on 6
Slide 20: For Investor Queries
For Investor Queries: Gagan Borana Madhusudan Dalmia Investor Relations and Enterprise Risk Management Investor Relations Email: gagan.borana@piramal.com Email: madhusudan.dalmia@piramal.com Our Websites:- Piramal Pharma Limited CDMO www.piramalpharma.com www.piramalpharmasolutions.com Complex Hospi